drugset / Trial / NCT02220348

A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically

NCT02220348

Phase 1 Completed 7 enrolled Forest Laboratories
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to determine the amount of linaclotide and its active metabolite (MM-419447) excreted in breast milk after multiple, once daily doses of linaclotide (72 μg, 145 μg, or 290 μg) in lactating women receiving the drug therapeutically.

Timeline

Start
2014-07-31
Primary completion
2019-05-31
Completion
2019-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Linaclotide Peptide 72 ug Oral
Subject Linaclotide Peptide 145 ug Oral
Subject Linaclotide Peptide 290 ug Oral